Amyloidoza - wybrane publikacje / Amyloidosis - selected publications:

1. Primary systemic amyloidosis: clinical and laboratory features in 474 cases.
RA Kyle, MA Gertz, Seminars in Hematology 1995

2. Diagnosis and treatment of amyloidosis.
Philip N Hawkins; Annals of Rheumatic Diseases, 1997

3. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients.
LB Lovat, MR Persay, S Madhoo, MB Pepys and PN Hawkins
An International Journal of Gastroenterology and Hepatology, 1998

4. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis.
Philip N. Hawkins
National Amyloidosis Centre, Royal Free and University College Medical School, London
Nephrology and Hypertension, 2002

5. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
MA Gertz, MQ Lacy, DA Gastineau, DJ Inwards, MG Chen, A Tefferi, RA Kyle and MR Litzow
Bonne Marrow Transplantation, 2000

6. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
MB Pepys, J Herbert, WL Hutchinson, GA Tennent, HJ Lachmann, JR Gallimore, LB Lovat, T Barfal, A Alanine,
C Hertel, T Hoffmann, R Jakob-Roetne, RD Norcross, JA Kemp, K Yamamura, M Suzuki, GW Taylor, S Murray,
D Thompson, A Purvis, S Kolstoe, SP Wood and PN Hawkins
Nature, 2002

7. Guidelines on the diagnosis and management of AL amyloidosis.
Members of the Guidelines Working Group of the UK Myeloma Forum
on behalf of the British Comitee for Standards in Haematology, 2004

8. High dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis: An 8-year study.
M Skinner, V Sanchrawala, DC Seldin, LM Dember, RH Falk, JL Berk, JJ Anderson, C O'Hara, KT Finn, CA Libbey,
J Wiesman, K Quillen, N Swan and DG Wright
American College of Physicians, 2004

9. Amyloidosis.
MA Gertz, MQ Lacy, A Dispenzieri, SR Haymann
Divison of Hematology, Mayo Clinic, 2005

10. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL):
A consensus opinion from the 10th internation symposium on amyloid and amyloidosis.

MA Gertz, R Comenzo, RH Falk, JP Fermand, BP Hazenberg, G Greateu, G Merlini, P Moreau,
P Ronco, V Sanchrawala, O Sezer, A Solomon and PN Hawkins
American Journal of Hematology, 2005

11. Diagnosis and management of the cardiac amyloidosis.
Rodney H. Falk; Contemporary Reviews in Cardiovascular Medicine, 2005

12. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK.
HB Goodman, JD Gillmore, HJ Lachmann, D Wechalekar, AR Bradwell and PN Hawkins
British Journal of Haematology, 2006

13. Therapy and management of systemic AL (primary) amyloidosis.
G. Palladini, V. Perfetti, G. Merlini; Swiss Med Weekly, 2006

14. The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary)
aymloidosis ineligible for stem cell transplantation.

G Palladini, V Perfetti, L Obici, R Caccialanza, A Semino, F Adami, G Cavallero, R Rustichelli, G Virga, G Merlini
Blood First Edition, 2003

15. Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis.
AD Wechalekar, HB Goodman, HJ Lachmann, M Offer JD Gillmore and PN Hawkins
Blood First Edition, 2006

16. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free
immunoglobulin light chains following chemotherapy.

HJ Lachmann, R Gallimore, JD Gillmore, HD Carr-Smith, AR Bradwell, MB Pepys and PN Hawkins
British Journal of Haematology, 2003

17. Serum NT-proBNP is a sensitive marker of myocardial dysfunction in AL amyloidosis.
G Palladini, F Lavatelli, P Russo, S Perlini, V Perfetti, T Bosoni, L Obici, AR Bradwell,
R Moratti and G Merlini
Circulation, 2003

18. Circulating amyloidogenic free light chains and serum NT-proBNP decrease simultaneously in association
with improvement of survival in AL.

G Palladini et all The American Society of Hematology, 2006

19. Nutritional status of outpatiens with systemic immunoglobulin light-chain amyloidosis.
R Caccialanza, G Palladini, C Klersy, H Cena, C Vagia, B Cameletti, P Russo, F Lavatelli
and G Merlini
The American Journal of Clinical Nutrition, 2006

20. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal
gammopathies and hereditary amyloid proteins.

RL Comenzo, P Zhou, M Fleisher, B Clark, J Teruya-Feldstein
Blood, 2006

21. Amyloidosis.
Mark B. Pepys, Center for Amyloidosis and Acute Phase Proteins
Royal Free and University College Medical School, London, United Kingdom
Annual Reviews of Medicine, 2006

Research and selection by KGB & KWT.